> ## Content Index
> Fetch the complete content index at: https://www.coios.me/llms.txt
> Use this file to discover other available public pages before exploring further.

# Trevogrumab, with or without garetosmab, against muscle loss on semaglutide in obesity
- URL: https://www.coios.me/trevogrumab-with-or-without-garetosmab-against-muscle-loss/
- Published: 2026-11-15T11:39:35.000Z
- Updated: 2026-11-15T12:14:38.000Z
- Description: A phase 2 trial in 975 adults with obesity tested GDF8 and activin A antibodies against semaglutide-related lean mass loss.
- Author: Daniel Ryan
- Tags: Tomorrow's world, Innovation in treatment, Obesity, diabetes and GLP-1, United States, #peer-reviewed, #new, #item, #source-2026-11, #score-75

COURAGE tested antibodies blocking GDF8 (trevogrumab) and activin A (garetosmab) for muscle loss during semaglutide-induced weight loss. The phase 2, double-blind, placebo-controlled trial randomised 975 adults with obesity at 60 US sites. Part A added placebo, trevogrumab 200 or 400 mg, or trevogrumab plus garetosmab to semaglutide for 26 weeks. Part B added placebo or trevogrumab 25 or 75 mg to semaglutide for 52 weeks. With semaglutide plus placebo, lean mass fell substantially by week 26\. Endpoints were lean mass, fat mass and bodyweight, not muscle strength or function, and all sites were in the US.

*Why it is interesting: Lean mass loss accompanies the rapid weight loss seen with GLP-1 receptor agonists. This large randomised trial tests whether blocking two negative regulators of muscle mass can offset that loss.*

Source

[The Lancet, 11 November 2026](https://doi.org/10.1016/S0140-6736%2826%2901953-7?ref=coios.me)

Paper

Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial

Authors

Mosenzon O, Rosenstock J, Raya JG, Grimsby JS, Calle RA, Cannon K et al.

DOI

10.1016/S0140-6736(26)01953-7

Type

Peer-reviewed article

Design

Two-part phase 2 double-blind placebo-controlled RCT, 60 US sites, n=975, 26-52 weeks, 2024-2025

Verdict

New finding

Driver

[Innovation in treatment](https://www.coios.me/d-treatment-innovation/)

Driver

[Obesity, diabetes and GLP-1](https://www.coios.me/d-obesity-diabetes/)